Fibrosis, Renal Transplant Rejection
Conditions
Keywords
Mesenchymal Stromal Cells, Allograft rejection, Fibrosis
Brief summary
This study will test the hypothesis that MSCs in combination with Everolimus facilitate Tacrolimus withdrawal, reduce fibrosis and decrease the incidence of opportunistic infections compared to standard tacrolimus dose.
Detailed description
Kidney transplantation has improved survival and quality of life for patients with end-stage renal disease. Despite excellent short-term results, long-term survival of transplanted kidneys has not improved accordingly in the last decades. Calcineurin inhibitors (CNI) have been the cornerstone of immunosuppressive therapy for many years, due to their efficacy in preventing acute rejection. However, CNI have nephrotoxic side effects that can directly contribute to renal dysfunction and compromise long-term outcomes. Consequently there is a strong interest in immunosuppressive (IS) regimens that maintain efficacy for the prevention of acute rejection, whilst reducing nephrotoxicity. In this perspective the combination of mesenchymal stromal cells (MSCs) with a mTor inhibitor (Everolimus (Certican®)) might be an optimal strategy to facilitate CNI (tacrolimus) withdrawal. MSCs have IS properties and roles in tissue repair and everolimus is a proliferation signal inhibitor with potent immunosuppressant effects. In experimental studies the combination of mTor inhibitor and MSCs was shown to attenuate alloimmune responses and to promote allograft tolerance. In total 70 de novo renal recipients, 18-75 years of ages will be recruited from the transplant clinics of the LUMC. Thirty five of these patients will be included in the Certican/ and MSC group and 35 patients in the Certican/ standard dose tacrolimus group. Patients of the MSC treated groups will receive two doses of autologous BM derived MSCs IV, 7 days apart, 6 and 7 weeks after transplantation in combination with Certican® (1.5 mg b.i.d.). At the time of the second MSC infusion tacrolimus will be withdrawn in 2 weeks (after 1 week dose of tacrolimus will be halved, after 2 weeks stopped). Patients in the control group will receive Certican® (1.5 mg b.i.d.) and standard dose tacrolimus (through levels 6-8 ng/ml after 6 weeks). Primary goal is evaluate whether concentration-controlled Certican® with MSCs compared to Certican® with standard tacrolimus in renal transplant recipients reduces fibrosis by quantitative Sirius Red scoring.
Interventions
DRUGMesenchymal Stromal Cells
Two doses of autologous bone marrow (BM) derived MSCs IV, 7 days apart, 6 and 7 weeks after transplantation. Doses of MSCs will be 1-2x10\^6 million MSCs per/kg body weight
Sponsors
Leiden University Medical Center
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Subject is willing to participate in the study, must be able to give informed consent and the consent must be obtained prior to any study procedure. * Recipients of a first kidney graft from a deceased, living-unrelated or non-HLA identical living related donor \> 50 years of age. * Panel Reactive Antibodies (PRA) ≤ 10%. * Patients must be able to adhere to the study visit schedule and protocol requirements. * If female and of child-bearing age, subject must be non-pregnant, non-breastfeeding, and use adequate contraception.
Exclusion criteria
* Double organ transplant recipient. * Biopsy proven acute rejection (according to the Banff criteria) in the first 6 weeks after transplantation. * Patients with evidence of active infection or abscesses (with the exception of an uncomplicated urinary tract infection) before MSC infusion. * Patients suffering from hepatic failure. * Patients suffering from an active autoimmune disease. * Patients who have had a previous BM transplant. * A psychiatric, addictive or any disorder that compromises ability to give truly informed consent for participation in this study. * Use of any investigational drug after transplantation. * Documented HIV infection, active hepatitis B, hepatitis C or TB according to current transplantation inclusion criteria. * Subjects who currently an active opportunistic infection at the time of MSC infusion (e.g., herpes zoster \[shingles\], cytomegalovirus (CMV), Pneumocystis carinii (PCP), aspergillosis, histoplasmosis, or mycobacteria other than TB, BK) after transplantation. * Malignancy (including lymphoproliferative disease) within the past 2-5 years (except for squamous or basal cell carcinoma of the skin that has been treated with no evidence of recurrence) according to current transplantation inclusion criteria. * Known recent substance abuse (drug or alcohol). * Contraindications to undergo a BM biopsy. * Patients who are recipients of ABO incompatible transplants. * Cold ischemia time \>30 hrs. * Patients with severe total hypercholesterolemia (\>7.5 mmol/L) or total hypertriglyceridemia (\>5.6 mmol/L) (patients on lipid lowering treatment with controlled hyperlipidemia are acceptable).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fibrosis by quantitative Sirius Red scoring of MSC treated and untreated groups | at 6 months compared to 4 weeks post transplant |
Secondary
| Measure | Time frame |
|---|---|
| Number of participants with CMV and BK infection an other opportunistic infections between groups | 6 months |
| Number of participants with adverse events | 6 months |
| Renal function and proteinuria | 6 months |
| Presence of donor specific antibodies and immunologic monitoring | 6 months |
| Progression of subclinical cardiovascular disease in the different treatment groups bij assessing echocardiographic parameters | 6 months |
| composite end point efficacy failure (biopsy proven acute rejection, graft loss or death) | 6 months |
Countries
Netherlands
Outcome results
None listed